Results 71 to 80 of about 23,326 (221)

Facial erythema after the treatment of dupilumab in SLE patient

Allergy, Asthma & Clinical Immunology, 2020
Background Dupilumab is a receptor antagonist binding to the alpha subunit of the interleukin-4 receptor. Through binding to it, dupilumab inhibits signaling of both IL-4 and IL-13, the representative Th2 biomarkers.
Dong Hyek Jang, Jae In Lee, Joo Yoon Bae, Hye Jung Jung, Mi Yeon Park, Jiyoung Ahn   +5 more
doaj   +1 more source

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran, Meier, Katharina, Solimani, Farzan   +2 more
core   +1 more source

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events

Journal for ImmunoTherapy of Cancer
Background Dupilumab has been added to National Cancer Comprehensive Network guidelines as a therapeutic strategy for managing certain cutaneous immune-related adverse events (cirAEs) from immune checkpoint blockade (ICB).
Shadmehr Demehri, Kerry L Reynolds, Yevgeniy R Semenov, Matthew Tran, Nicole R LeBoeuf, Suzanne Xu, Guihong Wan, Bonnie W Leung, Emma Beagles, Sara Khattab, Cameron Moseley, Chuck Lin, Marjan Azin, Ninghui Hao   +13 more
doaj   +1 more source

Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic dermatitis [PDF]

, 2022
Priyanka Anand, Sebastian Schneeweiß, Arash Mostaghimi, Maria C. Schneeweiss   +3 more
openalex   +1 more source

Cytokine and Lipid Mediator Regulation of Group 2 Innate Lymphoid Cells (ILC2s) in Human Allergic Airway Disease. [PDF]

, 2017
The recent discovery of group 2 innate lymphoid cells (ILC2s) has caused a paradigm shift in the understanding of allergic airway disease pathogenesis.
Cavagnero, Kellen, Doherty, Taylor A
core   +2 more sources

Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma

Respiratory Medicine Case Reports
Dupilumab is a monoclonal antibody that has recently been introduced for the treatment of asthma. It has the potential to significantly alter the progression and severity of T2 -dependent diseases, including severe asthma.
Agnieszka Gawlewicz-Mroczka, Marek Przybyszowski, Grażyna Bochenek, Maria Mroczka, Krzysztof Sładek   +4 more
doaj   +1 more source

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases [PDF]

, 2021
Jennifer D. Hamilton, Sivan Harel, Brian N. Swanson, William R. Brian, Zhen Chen, Megan S. Rice, Nikhil Amin, Marius Ardeleanu, Allen Radin, Brad Shumel, Marcella Ruddy, Naimish Patel, Gianluca Pirozzi, Leda Mannent, Neil M.H. Graham   +14 more
openalex   +1 more source

Inhalation therapy in the next decade : Determinants of adherence to treatment in asthma and COPD [PDF]

, 2018
Peer reviewedPublisher ...
Amaducci, Sandro, Bacci, Elena, Baldacci, Sandra, Bartoli, Maria L., Beghi, Gianfranco M., Benfante, Alida, Brighindi, Sara, Casali, Lucio, Castiglia, Daniela, Cazzola, Mario, Celi, Alessandro, Cianchetti, Silvana, Colombo, Giorgio, Crimi, Claudia, d'Alcontres, Martina Stagno, Dente, Federico L., Di Maria, Annalisa, Di Maria, Giuseppe, Donner, Claudio F., Hui Xin, Shaylynn Yu, Latorre, Manuela, Lavorini, Federico, Maio, Sara, Mannini, Claudia, Messina, Riccardo, Paggiaro, Pier Luigi, Pignatti, Patrizia, Pistolesi, Massimo, Price, David, Scichilone, Nicola, Simoni, Marzia, Spanevello, Antonio, Tan, Shwana, Torchio, Roberto, Viegi, Giovanni, Visca, Dina, Wouters, Emiel F.M.   +36 more
core   +5 more sources

Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels

Dermatology and Therapy
Introduction In chronic spontaneous urticaria (CSU), interleukin (IL)-4 and IL-13 may promote mast cell activation directly via IL-4 receptor expression, or indirectly via upregulated immunoglobulin E (IgE) production.
Marcus Maurer, Thomas B. Casale, Sarbjit S. Saini, Moshe Ben-Shoshan, Elizabeth Laws, Jennifer Maloney, Deborah Bauer, Allen Radin, Melanie Makhija   +8 more
doaj   +1 more source

Real-World Effectiveness and Safety of Dupilumab for the Treatment of Moderate to Severe Atopic Dermatitis in Indian Patients

, 2021
Sandipan Dhar, Abhishek De, Sahana M. Srinivas   +2 more
openalex   +1 more source